[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630214":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":7,"responsibleParty":8,"collaborators":7,"id":13,"slug":7,"hasResults":14,"nctId":15,"briefTitle":16,"officialTitle":17,"acronym":7,"eligibilityCriteria":18,"healthyVolunteers":14,"sex":19,"minAge":20,"maxAge":7,"enrollmentInfo":21,"targetDuration":7,"studyType":24,"phases":7,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":7},{"fullName":5,"class":6},"Shengjing Hospital","OTHER",null,{"type":9,"investigatorFullName":10,"investigatorTitle":11,"investigatorAffiliation":12,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Jianyi Li","Principal Investigator","Liaoning Cancer Hospital & Institute","100630214",false,"NCT07484763","Predicting Recurrence in HR+\u002FHER2- Early Breast Cancer","A Single-Center Retrospective Study to Develop a Nomogram for Predicting Recurrence in HR+\u002FHER2- Early Breast Cancer Using Real-World Data","Inclusion Criteria:\n\n* Histopathologically confirmed invasive breast ductal carcinoma or lobular carcinoma;\n* Molecular subtype of HR+\u002FHER2- (ER ≥ 10%, and HER2 immunohistochemistry 0\u002F1+ or 2+ without amplification confirmed by FISH);\n* Received standardized surgical treatment and postoperative adjuvant (or preoperative neoadjuvant) endocrine therapy;\n* Complete follow-up data available.\n\nExclusion Criteria:\n\n* Presence of distant metastasis (Stage IV) at diagnosis\n* Male breast cancer\n* Missing key clinicopathological data or loss to follow-up\n* HER2 immunohistochemistry 3+ or 2+ with amplification confirmed by FISH\n* Triple-negative breast cancer","FEMALE","18 Years",{"count":22,"type":23},500,"ESTIMATED","OBSERVATIONAL","Hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative (HR+\u002FHER2-) breast cancer constitutes approximately 70% of all breast cancer cases. Although early-stage patients generally have favorable outcomes following standard surgery and adjuvant endocrine therapy, long-term follow-up data reveal a distinct \"bimodal\" or \"long-tail\" recurrence pattern, with risks persisting for decades. Recent landmark trials (e.g., NATALEE, MonarchE) have established that combining CDK4\u002F6 inhibitors with endocrine therapy significantly improves invasive disease-free survival (iDFS) in high-risk populations. However, the stringent enrollment criteria of these randomized controlled trials may not fully capture the heterogeneity of real-world patients. Reliance on binary cut-off values (e.g., nodal status alone) risks misclassifying biologically high-risk individuals with low anatomical burden, leading to either undertreatment or overtreatment. There is an urgent clinical need for a multidimensional, individualized risk assessment tool to guide escalated therapy decisions.",[27],"Breast Cancer, HR+\u002FHER2- Early-Stage",[29,30,31,32],"Breast Cancer","HR+\u002FHER2-","Nomogram","Recurrence","NOT_YET_RECRUITING","2026-03-16",{"date":36,"type":37},"2026-03-20","ACTUAL",{"date":39,"type":23},"2026-04-01",{"date":41,"type":23},"2027-04-01",{"name":5,"class":6}]